Regulatory Considerations Specific to Liposome Drug Development as Complex Drug Products
Frontiers in Drug Delivery
volume 2
DOI: 10.3389/fddev.2022.901281
EISSN:
2674-0850
Repository
Description
Nearly a half-century after original liposome discovery as a prospective lipid pharmaceutical carrier, the global liposomal drug delivery market has increased dramatically, with an annual market growth rate of 13.2%, valued at ∼$6,993 million by 2027. As an intrinsically complex delivery system, liposomal formulations face much greater characterization and regulatory review challenges than traditional small molecule drugs and biologics. Due to rapid liposomal drug development, both European Medicines Agency (EMA) and US Food and Drug Administration (FDA) now provide regulatory guidance for new liposomal drug application reviews. The expanding global liposome drug market and associated driving forces for increased research and development (R&D) in novel liposomal products are key factors propelling liposomal drug interests. We review and compare EU and US regulations on liposomal drug submissions, and provide insights into regulatory strategies throughout the entire liposomal drug development process. This addresses current gaps noted between liposome-based drug development in research labs and current regulatory guidance for liposomal drug approvals in order to facilitate more efficient, less costly, and less risky complex drug development.
Affiliations
- California Health Sciences University
Publisher
Frontiers Media SA
Citations
-
A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents. BioNanoSci (2022). , 12, 274. https://doi.org/10.1007/s12668-022-00941-x
-
Doxil - the First FDA-Approved Nano-Drug: Lessons Learned. J. Controlled Release (2012). , 160, 117. https://doi.org/10.1016/j.jconrel.2012.03.020
-
A Brief Review on QbD Approach on Liposome and the Requirements for Regulatory Approval. Rese. Jour. Pharm. Technol (2019). , 12, 4057. https://doi.org/10.5958/0974-360X.2019.00699.1
-
Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics (2017). , 9, 12. https://doi.org/10.3390/pharmaceutics9020012
-
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Chronic Diseases in America. (2022). .
-
Draft Guidance on Doxorubicin Hydrochloride. (2014).
-
Drug Products, Including Biological Products, that Contain Nanomaterials. (2017).
-
Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability, and Labeling Documentation. (2018).
-
Transforming Nanomedicine Manufacturing toward Quality by Design and Microfluidics. Adv. Drug Deliv. Rev (2018). , 128, 115. https://doi.org/10.1016/j.addr.2018.04.004
-
CHMP Assessment Report Doxorubicin SUN. Eur. Medicines Agency (2011). .
-
Surface Coatings: General Issues for Consideration Regarding Parenteral Administration of Coated Nanomedicine Products. (2013).
-
Non-Biological Complex Drugs. (2015). https://doi.org/10.1007/978-3-319-16241-6
-
The Similarity Question for Biologicals and Non-biological Complex Drugs. Eur. J. Pharm. Sci (2015). , 76, 10. https://doi.org/10.1016/j.ejps.2015.04.010
-
Market Research. Liposomal Drugs Market – Global Industry Trends and Forecast to 2028 | Data Bridge Market Research. (2021). .
-
Long Circulating Liposomes: Challenges and Opportunities. Ther. Deliv (2018). , 9, 857. https://doi.org/10.4155/tde-2018-0035
-
Global Summit on Regulatory Science 2019 Nanotechnology and Nanoplastics. (2019).
-
Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product. (2013). .
-
European Medicines Agency-Food and Drug Administration Pilot Programme for Parallel Assessment of Quality-By-Design Applications: Lessons Learnt and Questions and Answers Resulting from the First Parallel Assessment. (2013). .
-
EMA-FDA Pilot Program for Parallel Assessment of Quality-By-Design Applications: Lessons Learnt and Q&A Resulting from the First Parallel Assessment. (2013).
-
Recent Advancements in Liposome Technology. Adv. Drug Deliv. Rev (2020). , 156, 4. https://doi.org/10.1016/j.addr.2020.06.022
-
Design of Liposomes as Drug Delivery System for Therapeutic Applications. Int. J. Pharmaceutics (2021). , 601, 120571. https://doi.org/10.1016/j.ijpharm.2021.120571
-
ICH Quality Implementation Working Group - Integrated Implementation Training Workshop. Workshop A: Des. Space (2010). .
-
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8(R2). (2009).
-
International Pharmaceutical Regulators Programme (IPRP). (2022). .
-
Development of Liposomes Using Formulation by Design: Basics to Recent Advances. Chem. Phys. Lipids (2019). , 224, 104764. https://doi.org/10.1016/j.chemphyslip.2019.03.017
-
Innovation for Generic Drugs: Science and Research under the Generic Drug User Fee Amendments of 2012. Clin. Pharmacol. Ther (2019). , 105, 878. https://doi.org/10.1002/cpt.1364
-
Design of Experiments (DoE) in Pharmaceutical Development. Drug Dev. Ind. Pharm (2017). , 43, 889. https://doi.org/10.1080/03639045.2017.1291672
-
Office of Generic Drugs, 2019 Annual Report, Ensuring Access to Safe, Affordable, and Effective Generic Drugs. U.S. Food Drug Adm (2020). .
-
Manual of Policies and Procedures (MAPP 5016.1): Applying ICH Q8 (R2), Q9, and Q10 Principles to CMC Review FDA. (2011).
-
Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients with Visceral Leishmaniasis. Front. Med (2021). , 8, 766400. https://doi.org/10.3389/fmed.2021.766400
-
Multivesicular Liposome (Depofoam) in Human Diseases. Iran J. Pharm. Res (2020). , 19, 9. https://doi.org/10.22037/ijpr.2020.112291.13663
-
In Vitro-In Vivo Correlation for Complex Non-oral Drug Products: Where Do We Stand?. J. Controlled Release (2015). , 219, 644. https://doi.org/10.1016/j.jconrel.2015.09.052
-
Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective. AAPS J (2017). , 19, 1669. https://doi.org/10.1208/s12248-017-0142-0
-
Liposome Drug Delivery Market Size Worth $6,992.95 Million, Globally, by 2027 at 8.8% CAGR - Exclusive Report by the Insight Partners. (2021). .
-
Challenges in Implementing Quality by Design - an Industry PerspectiveBioProcess International. (2015). .
-
U.S. Government Accountability Office (GAO). Report to Congressional Requesters on Generic Drugs — FDA Should Make Public its Plans to Issue and Revise Guidance on Nonbiological Complex Drugs. (2017).
-
A Review of Patisiran (ONPATTRO) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis. Neurol. Ther (2020). , 9, 301. https://doi.org/10.1007/s40120-020-00208-1
-
Generic Drug User Fee Amendments of 2017, Title Iii, Fda Reauthorization Act of 2017, Pub. L. 115-52, §§ 301-307, 131 Stat. (2017).
-
Guideline on General Principles of Process Validation. (1987).
-
HHS Guidance for Industry Process Validation: General Principles and Practices (2011). (2011).
-
Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. FDA Draft Guidance. (2002).
-
Upcoming Product-specific Guidances for Complex Generic Drug Product Development | FDA. (2022). .
-
Lyophilized Liposome-Based Parenteral Drug Development: Reviewing Complex Product Design Strategies and Current Regulatory Environments. Adv. Drug Deliv. Rev (2019). , 56. https://doi.org/10.1016/j.addr.2019.03.003
-
Newly Approved Complex Drug Products and Potential Challenges to Generic Drug Development. (2020). .
View full text
